1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Carter Sinclair News Biolaxy Secures IND Approval For Oral Insulin

Carter Sinclair News: Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin).

 
PRLog - Nov. 25, 2009 - LA QUINTA, Calif. -- Carter Sinclair News: Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.

Carter Sinclair News: Diabetes is a disorder characteristic of high blood glucose and poor metabolism. The complications of diabetes often result in severe micro- and macro-vascular diseases, loss of vision, kidney failure, and amputation. Insulin, as an effective diabetic treatment, can slow down diabetic disease progression. However, insulin is given by multiple daily injections at present, which significantly hinders its use.

Oral drug administration is a preferred route. However, the gastrointestinal (GI) tract is designed to digest nutrients like proteins and presents significant challenges for oral insulin including enzyme degradation and poor absorption. Currently, there is no approved oral insulin product despite intensive research in this field.

Nodlin is developed with NOD technology, a patented bio-adhesive nano-particle oral delivery technology, to overcome the barriers of oral insulin.

"IND approval is a significant milestone achievement for Biolaxy," quoted from William Lee, CEO. "We have experienced long delay in the approval process due to regulatory uncertainties, but we are very happy now Biolaxy is back on track in full speed to develop urgently needed drugs for the patients."

About Diabetes and Insulin Treatment

Diabetes has reached epidemic stage. It is estimated that there are 30-40 million diabetic patients in China with 1.2 million new cases each year. Insulin is a key diabetic treatment with worldwide market value close to $10 billion. Diabetic patients have to endure multiple daily injections for life and patients often are reluctant to use insulin despite the clinical proven benefits of early insulin treatment. Currently, insulin treatment in China particularly is under used.
Shanghai Biolaxy is a development stage biotech company and emerging leader in innovative delivery for biopharmaceuticals. Biolaxy was established in 2005 and is a wholly owned subsidiary of NOD Pharmaceuticals. Biolaxy uses patented platform technology, nano-particle oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide, interferon, human growth hormone and more.

Carter Sinclair Org is non-profit organization that helps monitor health status, inform and educate people about health issues. Research for new approach and modern solutions to health problems. For more information please visit www.cartersinclair.org.  Email at info@cartersinclair.org

# # #

Carter Sinclair Org is non-profit organization that helps monitor health status, inform and educate people about health issues. Research for new approach and modern solutions to health problems. For more information please visit www.cartersinclair.org. Email at info@cartersinclair.org

--- End ---

Click to Share

Contact Email:
***@cartersinclair.org Email Verified
Source:Carter Sinclair Org
Phone:(760) 360-6211
Zip:92253-4241
City/Town:La Quinta - California - United States
Industry:Diabetes
Tags:carter sinclair, carter sinclair diabetes, carter sinclair korea
Shortcut:prlog.org/10428321
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share